FIG. 1

FIG. 2

FIG. 3

FIG. 4

FIG. 5

FIG. 6

FIG. 7

pA2HG1apgpt

FIG. 8A

pA2HuKapgpt

FIG. 8B

FIG. 9A

FIG. 9B

$y = 7.0802 - 5.9612 \, x \quad R^2 = 0.944$

I-125 murine A2 IgG
Estimated Avg. Ka = 0.5×10^9

FIG. 10A

$y = 25.953 - 15.306 \, x \quad R^2 = 0.972$

I-125 chimeric A2 IgG
Estimated Avg. Ka = 1.8×10^9

FIG. 10B

FIG. 11

FIG. 12

1
Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
10

21
Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly
30

41
Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser
50

61
Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile
70

81
Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro
90

101
Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu
110

121
Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp
130

141
Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu
150

FIG. 13

FIG. 14A

FIG. 14B

```
1
Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
                              10

21
Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly
                              30

41
Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser
                              50

61
Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile
                              70

81
Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro
                              90

101
Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu
                             110

121
Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp
                             130

141
Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu
                             150
```

FIG. 15

GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGT
AspIleLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgvalSer

TTCTCCTGCAGGGCCAGTCAGTTCGTTGGCTCAAGCATCCACTGGTATCAGCAAAGAACA
PheSerCysArgAlaSerGlnPheValGlySerSerIleHisTrpTyrGlnGlnArgThr

AATGGGTTCCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCTCTGGATCCCTTCC
AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

AGGTTTAGTGGCAGTGGATCAGGGACAGATTTACTCTTAGCATCAACACTGTGGAGTCT
ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer

GAAGATATTGCAGATTATTACTGTCAAGAAAGTCATAGCTGGCCATTCACGTTCGGCTCG
GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

GGGACAAATTTGGAAGTAAAA
GlyThrAsnLeuGluValLys

FIG. 16A

GAAGTGAAGCTTGAGGAGTCTTGGAGGAGGCTTGGTGTGCAACCTGGAGGATCCATGAAACTC
GluValLysLeuGluGluSerGlyGlyGlyLeuValGlnProGlyGlySerMetLysLeu

TCCTGTGTTGCCTCTGGATTCATTTCAGTAACCACTGGATGAACTGGGTCCGCCAGTCT
SerCysValAlaSerGlyPheIlePheSerAsnHisTrpMetAsnTrpValArgGlnSer

CCAGAGAAGGGGCTTGAGTGGGTTGCTGAAATTAGATCAAAATCTATTAATTCTGCAACA
ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr

CATTATGCGGAGTCTCTGTGAAAGGGAGGTTCACCATCTCAAGAGATGATTCCAAAGTGCT
HisTyrAlaGluSerValLysGlyArgPheThrIleSerArgAspAspSerLysSerAla

GTGTACCTGCAAATGACCGACTTAAGAAACTGAAGACACTGGCGTTTATTACTGTTCCAGG
ValTyrLeuGlnMetThrAspLeuArgThrGluArgThrGlyValTyrTyrCysSerArg

AATTACTACGGTAGTACCTACGACTACTGGGGCCAAGGCACCACTCTCACAGTGTCC
AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer

FIG. 16B

PAIN

FIG. 18

EMS

FIG. 17

SWOLLEN JOINTS

Patient Number

1-5

6-9

Percent of Day 1

Day

FIG. 20

RITCHIE ARTICULAR INDEX

Patient Number

1-5

6-9

Percent of Day 1

Day

FIG. 19

FIG. 22

FIG. 21

FIG. 23

FIG. 24

FIG. 25

FIG. 26A

FIG. 26B

FIG. 27

FIG. 28

FIG. 29

FIG. 30

FIG. 31A

FIG. 3IB

FIG. 31C

FIG. 32

FIG. 33A

FIG. 33B

p55-df2

$y=102.51-1.6608e-2x$
$R^2=0.981$

bound (cpm)/Free (pm)

bound (cpm)

FIG. 33D

p55-sf2

$y=97.625-1.7489e-2x$
$R^2=0.963$

bound (cpm)/Free (pm)

bound (cpm)

FIG. 33C

p75-sf2

$y = 196.56 - 2.9952e - 2x$

$R^2 = 0.981$

bound (cpm)/Free (pm)

bound (cpm)

FIG. 33F

p55-sf3

$y = 109.39 - 2.0858e - 2x$

$R^2 = 0.954$

bound(cpm)/Free (pm)

bound (cpm)

FIG. 33E

p75P-sf3

$y=193.31-7.3370e-2x$

$R^2=0.972$

bound (cpm)/Free (pm)

bound (cpm)

FIG. 33H

p75P-sf2

$y=236.42-3.4611e-2x$

$R^2=0.967$

bound (cpm)/Free (pm)

bound (cpm)

FIG. 33G

* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 *versus* pre-infusion
† p ≤ 0.05, †† p ≤ 0.01, ††† p ≤ 0.001 *versus* change in
   placebo group

FIG. 34